The Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine has been offered to nonallergic ≥16-year-old Israeli adults since December 19, 2020. Data regarding factors associated with vaccine ineffectiveness are limited. The aim of this study is to assess the impact of hepatic fibrosis on the efficacy of the BioNTech vaccine. Serum severe acute respiratory syndrome coronavirus 2 spike immunoglobulins (S IgG) obtained at least 7 days following vaccination completion was correlated with the prevaccine calculated Fibrosis-4 (FIB-4) score among 719 employees in the Hadassah Medical Center, Jerusalem. Positive vaccine response (S IgG levels ≥ 19 AU/mL) was found in 708 of 719 individuals (98.5%). Vaccine failure (S IgG levels < 19) was found in 11 (1.5%); of these, 7 were immunosuppressed. Mean FIB-4 available in 501 of 708 vaccine responders was 1.13 ± 0.66, mean age 51.4 ± 12.4 years (29.3% males), and mean S IgG titers 239.7 ± 86.1 AU/mL. Similar to the general population, 70.5% had normal FIB-4 (<1.3), 26.8% undetermined FIB-4 (1.3-2.67), and 2.7% advanced FIB-4 (>2.67). When divided into response subgroups, 158 of 501 individuals (30.1%) with IgG titers 19-100 AU/mL had a mean FIB-4 of 1.48 ± 0.82; 198 (39.5%) with IgG titers 101-200 AU/mL had mean FIB-4 of 1.22 ± 0.76; 83 (16.6%) with titers 201-300 AU/mL had mean FIB-4 of 1.04 ± 0.48; 38 (7.6%) individuals with IgG titers 301-400 AU/ml had a mean FIB-4 of 1.08 ± 0.63; and 121 (24.2%) with IgG titers >400 AU/mL had mean FIB-4 of 1.18 ± 0.87. Increased FIB-4, age, and male gender significantly correlated with lower postvaccine IgG titers (P < 0.001). FIB-4 results were confirmed using FibroScan data displaying advanced fibrosis impact on weakened COVID-19 vaccine response. Conclusion: Immune suppression, older age, male gender, and advanced chronic liver disease are risk factors for lower vaccine response. The FIB-4 provides a simple tool to prioritize candidates for third-dose vaccine booster.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110948 | PMC |
| http://dx.doi.org/10.1002/hep4.1901 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Building a Fast Response Capability for Emerging Infectious Diseases Within the Biomedical Advanced Research and Development Authority.
Health Secur
January 2025
Robert A. Johnson, PhD, is Director, Medical Countermeasures Programs, and Gary L. Disbrow, PhD, is Director, Center for Biomedical Advanced Research and Development Authority (BARDA), Washington, DC. Terence M. Barnhart, PhD, is Senior Strategy Implementation Leader, Tunnell Government Services, Inc. (Contractor Supporting BARDA), Washington, DC.
From influenza to COVID-19, emerging infectious diseases have taken a heavy toll on lives and resources. Emerging infectious diseases represent one of the largest threats to national security. The primary mission of the Center for Biomedical Advanced Research and Development Authority (BARDA), within the US Administration for Strategic Preparedness and Response, is to support the advanced development of medical countermeasures (MCMs) for public health security threats, including select infectious diseases.
View Article and Find Full Text PDF[Pharmacovigilance of COVID-19 Vaccines in Brazil: Actions Taken, Lessons Learned, and Next StepsFarmacovigilancia de las vacunas contra la COVID-19 en Brasil: medidas adoptadas, enseñanzas extraídas y próximos pasos].
Rev Panam Salud Publica
January 2025
Ministério da Saúde Brasília-DF Brasil Ministério da Saúde, Brasília-DF, Brasil.
Objective: To document the actions taken by Brazil's National Immunization Program for the pharmacovigilance of COVID-19 vaccines.
Methods: Documentary research on the period 2020 to 2023. Documentary sources from the national Ministry of Health during COVID-19 vaccination were used to analyze and interpret the actions taken.
Objectives: We assessed the transmission of SARS-CoV-2 and vaccine receipt in a representative sample of wet market workers in a highly dense, low-income setting. Wet markets are key in many Asian settings, including Dhaka, Bangladesh, for fresh food, including animal protein.
Methods: During early 2022, we assessed the prevalence of anti-SARS-CoV-2 antibodies in a random sample of poultry and vegetable workers in 15 wet markets, and investigated associations with socio-demographic characteristics and COVID-19 vaccination.
Monkeypox: a re-emergent virus with global health implications - a comprehensive review.
Trop Dis Travel Med Vaccines
January 2025
Department of Botany and Microbiology, Faculty of Science, Damanhour University, Damanhour, Egypt.
Monkeypox virus (MPXV) is an enclosed, double-stranded DNA virus from the Orthopoxvirus genus, which also contains variola, vaccinia, and cowpox. MPXV, which was once confined to West and Central Africa, has recently had a rebound, spreading beyond its original range since 2017. The virus is distinguished by its unique morphology, which includes an oval or brick-shaped structure and a complex lipid and protein makeup.
View Article and Find Full Text PDFAssociation between COVID-19 anxiety syndrome and COVID-19 vaccine hesitancy in the postpandemic era: a cross-sectional study in Hong Kong.
BMC Public Health
January 2025
Department of Social Work, Hong Kong Baptist University, Hong Kong, China.
Background: The COVID-19 pandemic has had profound psychophysiological and socioeconomic effects worldwide. COVID-19 anxiety syndrome (CAS) is a specific cluster of maladaptive coping strategies, including perseveration and avoidance behaviours, in response to the perceived threat and fear of COVID-19. CAS is distinct from general COVID-19 anxiety.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!